A. Yan

Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis.

J. Trotter, J. Frias, C. Guy, 2020, Gastroenterology.

140-LB: NGM313, a Novel Activator of b-Klotho/FGFR1c, Improves Insulin Resistance and Reduces Hepatic Fat in Obese, Nondiabetic Subjects

J. Olefsky, L. Morrow, M. Bashir, 2019, Diabetes.

Aldafermin (NGM282) reduces the cross-linked pro-peptides of type III collagen PRO-C3X, a novel biomarker, in non-alcoholic steatohepatitis and primary sclerosing cholangitis patients

M. Karsdal, J. Trotter, G. Hirschfield, 2020, Journal of Hepatology.